J4

• 临床研究 • 上一篇    下一篇

89SrCl2治疗多发性骨转移癌骨痛与ET、CGRP、TXB2、6-K-PGF1a的关系

孙文伟1, 魏丽琴1, 谭 平2, 马庆杰1   

  1. 1.吉林大学中日联谊医院核医学科,吉林 长春 130033;2.吉林大学中日联谊医院呼吸内科,吉林 长春 130033
  • 收稿日期:2005-11-17 修回日期:1900-01-01 出版日期:2007-05-28 发布日期:2007-05-28
  • 通讯作者: 马庆杰

Relationship between therapeutic effects of 89SrCl2 on osteodynia induced by multiple bone metastases and ET,CGRP,TXB2 and6-K-PGF1a

SUN Wen-wei1,WEI Li-qin1,TAN Ping2,MA Qing-jie1   

  1. 1.Department of Nuclear Medicine,China-Japan Union Hospital,Jilin University,Changchun 130033, China;2.Department of Respiratory Medicine,China-Japan Union Hospital,Jilin University,Changchun 130033, China
  • Received:2005-11-17 Revised:1900-01-01 Online:2007-05-28 Published:2007-05-28
  • Contact: MA Qing-jie

摘要: 目的:探讨89SrCl2治疗多发性骨转移癌骨痛与内皮素(ET)、降钙素基因相关肽(CGRP)、血栓素B2(TXB2)及6-酮-前列腺素F1a(6-K-PGF1a)的关系。方法: 39例多发性骨转移癌患者行89SrCl2内照射治疗,采用放射免疫分析法检测治疗前和治疗后1、3及6个月时患者血浆ET、CGRP、TXB2、6-K-PGF1a含量,并计算ET/CGRP 。结果:ET含量,治疗后1个月较治疗前无明显变化,治疗后3及6个月与治疗前及治疗后1个月相比均明显升高 (P<0.01);CGRP含量,治疗后1个月与治疗前比较明显升高(P<0.05);ET/CGRP比值,治疗前较治疗后1个月无明显变化,治疗后3及6个月与治疗前及治疗后1个月比较均明显升高(P<0.01);TXB2含量治疗前后无明显变化;6-K-PGF1a含量,治疗前较治疗后1个月无明显变化,治疗后3及6个月与治疗前及治疗后1个月比较均显著升高(P<0.01)。结论:89SrCl2治疗多发性骨转移癌骨痛的止痛作用与ET、CGRP、6-K-PGF1a、以及ET与CGRP的平衡有关。

关键词: sup>SrCl2<, sub>, 多发性骨转移癌, 内皮素, 降钙素基因相关肽, 血栓素B2<, sub>, 6-酮-前列腺素F1a<, sub>

Abstract: Abstract:Objective To explore the relationship between therapeutic effects of 89SrCl2 on osteodynia induced by multiple bone metastasis and ET,CGRP,TXB2 and 6-K-PGF1a.Methods 89SrCl2 treatment was used in 39 cases of multiple bone metastasis,the serum content of ET,CGRP,TXB2 and 6-K-PGF1a were detected with radioimmunological method pre-treatment and 1, 3,6 months post-treatment,respectively;the ET/CGRP value was calculated.Results The content of ET showed no obvious changes 1 month post-treatment compared with pre-treatment.However,the ET contents increased significantly 3 and 6 months post-treatment compared with 1 month post-treatment and before treatment (P<0.01).CGRP content increased significantly 1 month post-treatment compared with pre-treatment (P<0.05).However,ET/CGRP value had no significant difference 1 month post-treatment compared with pre-treatment. ET/CGRP increased remarkably 3 and 6 months post-treatment compared with pre-treatment and 1 month post-treatment (P<0.01).Also,TXB2 content had no significant changes between pre- and post-treatment.While 6-K-PGF1a content demonstrated no obvious changes 1 month post-treatment compared with pre-treatment.6-K-PGF1a content increased markedly 3 and 6 months post-treatment compared with pre-treatment and 1 month post-treatment (P<0.01). Conclusion The mechanism of releasing pain through 89SrCl2 strategy is related to ET,CGRP,6-K-PGF1a and ET/CGRP.

Key words: sup>SrCl2<, sub>, multiple bone metastasis, ET, CGRP, TXA2<, sub>, 6-K-PGF1a<, sub>

中图分类号: 

  • R730.55